Company Filing History:
1 out of 20 
1 out of 237 Years Active: 2022
Title: The Innovative Contributions of Charlotte Dalba-Fribert
Introduction
Charlotte Dalba-Fribert is a notable inventor based in Gothenburg, Sweden. She has made significant contributions to the field of biotechnology, particularly in the treatment of cytomegalovirus (HCMV) infections. Her innovative work has led to the development of immunogenic compositions that hold promise for enhancing immune responses against this virus.
Latest Patents
Charlotte holds one patent titled "Compositions and methods for treatment of cytomegalovirus." This patent describes compositions and methods that utilize virus-like particles (VLPs) comprising Moloney Murine leukemia virus (MMLV) core proteins and HCMV epitopes. The invention recognizes that a combination of antigens can elicit beneficial immune responses, including both humoral and cellular responses.
Career Highlights
Throughout her career, Charlotte has worked with various organizations, including Variation Biotechnologies Inc. and Sorbonne Université. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of her notable coworkers include David E. Anderson and Anne-Catherine Fluckiger. Their collaborative efforts have further advanced the research and development of effective treatments for HCMV.
Conclusion
Charlotte Dalba-Fribert's innovative work in the field of biotechnology exemplifies the impact of dedicated inventors on public health. Her contributions to the treatment of cytomegalovirus highlight the importance of research and collaboration in developing effective medical solutions.